[go: up one dir, main page]

IN2014DN07483A - - Google Patents

Info

Publication number
IN2014DN07483A
IN2014DN07483A IN7483DEN2014A IN2014DN07483A IN 2014DN07483 A IN2014DN07483 A IN 2014DN07483A IN 7483DEN2014 A IN7483DEN2014 A IN 7483DEN2014A IN 2014DN07483 A IN2014DN07483 A IN 2014DN07483A
Authority
IN
India
Prior art keywords
ohepa
hetre
dgla
inhibition
esters
Prior art date
Application number
Inventor
Dave Coughlan
Bill Downes
John Climax
Mehar Manku
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of IN2014DN07483A publication Critical patent/IN2014DN07483A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.
IN7483DEN2014 2012-02-23 2013-02-25 IN2014DN07483A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602374P 2012-02-23 2012-02-23
PCT/EP2013/053677 WO2013124479A1 (en) 2012-02-23 2013-02-25 Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same

Publications (1)

Publication Number Publication Date
IN2014DN07483A true IN2014DN07483A (en) 2015-04-24

Family

ID=47915154

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7483DEN2014 IN2014DN07483A (en) 2012-02-23 2013-02-25

Country Status (6)

Country Link
US (3) US20130267598A1 (en)
EP (1) EP2817005A1 (en)
JP (1) JP2015508094A (en)
CN (1) CN104244941A (en)
IN (1) IN2014DN07483A (en)
WO (1) WO2013124479A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
KR20160132372A (en) * 2014-01-10 2016-11-18 디그너티 사이언스 리미티드 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA39718A (en) * 2014-04-09 2017-02-15 Dignity Sciences Ltd Compositions for treating skin conditions
SG10201912145VA (en) 2014-06-04 2020-02-27 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and use of same
MA41120A (en) 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
EP3294282A1 (en) * 2015-05-13 2018-03-21 DS Biopharma Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
CN108025181A (en) 2015-07-21 2018-05-11 艾菲穆恩有限公司 Compositions comprising 15-HEPE for use in the treatment or prevention of cancer and neurological diseases
IL318963A (en) 2015-12-18 2025-04-01 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (en) * 2021-04-15 2022-10-21 宋晓瑜 Method for preparing lavender acetate and lavender alcohol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
DE10121252A1 (en) * 2001-04-30 2002-11-07 Christos C Zouboulis Acne treatment
GB0611240D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
FR2906716B1 (en) 2006-10-06 2013-05-17 Clarins Lab USE OF A COSMETIC COMPOSITION FOR THE CARE OF OIL SKIN.
ITMI20070555A1 (en) * 2007-03-21 2007-06-20 Giuliani Spa COMPOSITION OF THE ACTIVITY OF INHIBITION ON THE 5 ALPHA-REDUCTASE
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof

Also Published As

Publication number Publication date
US20130274338A1 (en) 2013-10-17
US20130267598A1 (en) 2013-10-10
US20150094370A1 (en) 2015-04-02
CN104244941A (en) 2014-12-24
EP2817005A1 (en) 2014-12-31
JP2015508094A (en) 2015-03-16
WO2013124479A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
IN2014DN07483A (en)
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP4371616A3 (en) Compositions of obeticholic acid and methods of use
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
PH12012501755A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2013293116A8 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
IN2015DN01198A (en)
UA114656C2 (en) Novel pyridine derivatives
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
IL232515A0 (en) Nadph oxidase 4 inhibitors and pharmaceutical compositions containing the same
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
AU337887S (en) Allsaw
AU342358S (en) Dental bite block
UA115357C2 (en) Pyridin-4-yl derivatives
IN2014DN11078A (en)
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
WO2016060935A3 (en) Compositions and methods of improving the digestibility of animal feed
MX339361B (en) Alternan derivatives.
MX2021001790A (en) Solid compositions of triglycerides and uses thereof.
IN2015DN04074A (en)
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
AU337888S (en) Allsaw